Silver Book Fact

Teriparatide, or human recombinant PTH, has been shown to decrease vertebral fractures by 65% to 69%, and non-vertebral fragility fractures by around 53%.

Neer R, Arnaud C, Zanchetta J, Prince R, et al. Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis. NEJM. 2001; 344(19): 1434-41. http://content.nejm.org/cgi/content/abstract/344/19/1434

Reference

Title
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
Publication
NEJM
Publication Date
2001
Authors
Neer R, Arnaud C, Zanchetta J, Prince R, et al.
Volume & Issue
Volume 344, Issue 19
Pages
1434-41
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Risedronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by around 5% and hip BMD by 2% to 3% in postmenopausal women with osteoporosis.  
  • Raloxifene, a selective estrogen receptor modulator (SERM), has been shown to decrease vertebral fractures by up to 50% after 3 years.  
  • An increase in bone mineral density (BMD) testing and osteoporosis treatment was associated with a decrease in hip fracture incidence.  
  • Tools to Prevent Secondary Osteoporosis Fractures are Not Being Used
     
  • Reducing risk of fracture from 8% to 2% reduces the 5-year fracture incidence from approximately 34% to 10%.